Feedback Share Discussion Threads

[monkey puzzle] 02/6/2021 13:27

I thought you were having a robust discussion with ydder?

[ducatiman] 02/6/2021 12:06

Correct LR2. Let’s hope you are right about upcoming contracts. That would be a game changer and Trev would go silent.

[lr2] 02/6/2021 11:58

I'm not falling out with Duc. He's a good bloke that I've known for years. We're just having a discussion Monkey.

[monkey puzzle] 02/6/2021 11:46

Oh dear...LTHs falling out, never a good sign...and what's happened to the £5m btw?

[ducatiman] 02/6/2021 11:28

Trouble is LR2 that the company has failed to commercialise Texrad and its looking similar for bleepa. As good as the products are they have to be marketable.

[lr2] 02/6/2021 11:12

Trevor, you say that 'onlookers can only have an impression of the facts' and that I am therefore incorrect. Are you implying that you are not also just an onlooker at Feedback these days? You departed the company in 2017. Are you saying you still retain an insiders view of what is going on there? If so, how? I am advised that you did not leave the company on good terms so why would you have any better idea than me as to the current position of the company?

As I told you in an earlier post, I support Feedback because of the unique selling points of their products. TexRAD - more than the eye can see, Bleepa - no degradation of the original 'clinical image'. That is why I am here supporting Feedback.

Now, pray tell me, why are you spending time here knocking the company if not for a 4 year old grudge?

[ydderf] 02/6/2021 10:40

Necessarily onlookers can only have an impression of the facts because of regulatory restrictions, thus your account is not at all correct. Similarly on these boards, most of what is written is based on half-truths and groundless speculation, and there is little interest in the real because share holders who are mainly under water, might find it painful. This has the effect of chasing away any balanced views and anything critically written is perceived (as you show above) as being motivated by grudge. I would be happy to chat to you if it might help. It is a minor mystery to me that you consistently support Feedback when it has completely and totally changed to the point it is unrecognisable as the company you bought shares in years ago...

[lr2] 02/6/2021 10:06

You talk the company down whenever you appear Trevor, you refused to dispose of your shareholding in an orderly manner when you departed the board, are you sure you aren't harbouring a grudge against the company for the manner in which you departed?

You resigned from Feedback four years ago. Having disposed of your shares throughout 2017-18 in anything but an orderly manor, I see no reason why you should have greater knowledge of the company than any other outsider. I suspect you might wish to have an in-depth knowledge of Feedback now but I doubt that you do.

[ydderf] 02/6/2021 10:01

I have a natural interest in Feedback plc since I put together the 2014 RTO. I probably know more about Feedback than any other poster here

[lr2] 02/6/2021 09:00

Trevor, to reiterate, what USP's do your various companies offer? And why have you returned here now? What reasons do you have for that?

[ydderf] 02/6/2021 08:18

Shareholders here don't have to wonder they could just ask the Board what it is doing with TexRad. Meanwhile the five year share price chart is an eloquent comment on all that has happened since before and after the Company was 're-purposed'

[lr2] 01/6/2021 19:28

You might be right Duc. There have been plenty of articles that mention TexRAD usage in the last 17 months or so (79 in 2020 and 37 so far in 2021), it is not a dormant part of the company. We need the revenue from TexRAD to cover part of the monthly expenditure until another 4-5 trusts sign up to Bleepa. Even then, I'd be happier if Feedback continued to control it rather than sell it.

Edit at 19:30 on 04/06/21

Previously reported TexRAD count of 114 for 2020 also included 35 for 2021.
Now 79 in 2020 and 37 in 2021 (up from original 35 count of 01/06/21).

[ducatiman] 01/6/2021 19:17

Nice reply LR2. FF is here for a reason. I wonder what he knows, bet he still has insiders at Fdbk.
I think he wants Texrad.

[lr2] 01/6/2021 14:04

Thank you Leo.

Me and Trev do like a bit of banter.

[leoboy] 01/6/2021 13:57

excellent retort LR2 !

[lr2] 01/6/2021 13:33

"we can logically assign a 50/50 probability to good or bad news" - No, we can't, we live in an entropic world where disorder and chaos is normal. Good news/bad news flow is random not 50/50 assigned. Was it specifically a time for bad news and that's why the world got a pandemic? No, it was random chance unless you subscribe to the belief that the Chinese Communist Party released the virus on purpose to destroy opposition to their chances of conquering the world. As you get older you will definitely be getting more and more bad news than you did when you were young. The second law of thermodynamics says that entropy always increases with time.

"a decision that your original assessment of TexRad technology was flawed" - the technology is not flawed, it is still used. Only yesterday I discovered a new article titled "Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features" where TexRAD was used. I just don't post about these finds anymore as everyone on this board is concentrated on Bleepa and some people groaned when I kept posting about TexRAD - I try not to impose myself and my beliefs on the good folk here. It's not an either/or situation Trevor, we have Bleepa, Cadran PACS and TexRAD. Three strings to Feedback's bow.

I like USP's Trevor. TexRAD - more than the eye can see, Bleepa - no degradation of the original 'clinical image'. That's why I'm here.

Now what USP's do your various companies offer? And why have you returned here now? What reasons do you have for that?

There's no such thing as coincidence after all.

[ducatiman] 01/6/2021 12:07

We know you love LR2 really ydder. Obviously you are hoping to pick up Texrad on the cheap if the company fails.
As each day passes without news it seems more likely.

[ydderf] 01/6/2021 07:47

I think it is a pity that it isn't possible to have reasonable debate on these threads. I can understand it though while nearly all posters will be shareholders and only want to hear good news. The truth is it is impossible to know what lies ahead, but we can logically assign a 50/50 probability to good or bad news. This sad fact of life is never reflected in debate. LR2 for example has been a shareholder for years over which time the company has morphed into an entirely new business from the one he/she originally invested in, there are many other long term holders. My question is did you make a decision that your original assessment of TexRad technology was flawed and that you preferred to be invited in a start up (Bleeper)? My guess is that the answer is 'no' because nobody even Tom Oakley had no idea that Bleeper is what the Company would be doing a year or so after he was appointed.

[ydderf] 01/6/2021 07:32

The share price on the 8th June was 2.85

[coldspring] 28/5/2021 21:40

Good find LR2, lets hope some contracts get signed as a result

[lr2] 28/5/2021 20:53

Taking stock of messaging apps: using safe, secure and compliant clinical messaging to drive efficiencies, negate clinical risk and improve care delivery

17 Jun 2021 08:00 - 08:55 S - Specialist sessions 3

The European Commission’s Medical Device Directive states that any platform that ‘displays digital patient images for the purpose of diagnosis’ by clinicians should hold a CE mark as a regulated medical device. However, with the current prevalence of clinicians using mainstream messaging and clinical communication platforms without it, there is a considerable liability risk for both organisations and individual clinicians.

Healthcare organisations also have an obligation under GDPR as data controllers, which means that communication apps that contain patient information should include a data processing agreement between the manufacturer and any organisation whose employees are using it. This applies to apps offered to clinicians under a ‘freemium’ model, even if the organisation itself has not encouraged the use of the tool and, in many cases, its clinicians may be using it outside of the organisation's knowledge.

This panel discussion seeks to explore the broader benefits of using a safe, secure and compliant clinical communications platform, including integrating with other clinical systems; recording discussions as part of the patient record; and improving efficiencies and working practices for busy clinicians at a time when the elective care backlog is particularly challenging.

This session is delivered in partnership with Feedback Medical Ltd

Speakers

Darryn Hale, Senior Associate - DAC Beachcroft

Dr Tom Oakley, CEO - Feedback Medical Ltd

[ducatiman] 28/5/2021 12:34

If he walks away or the CO’ go bust he will have lost nothing but earned at least £250k.

[digger2779] 28/5/2021 12:10

Has Tom bought any shares here? I've only stayed put because Rory Shaw bought over 5 million in October 2020 which nearly doubled his holding.
Tom's had a raise and nice bonus so splash the cash matey. At least then we will know you are aligned with us and there wont be any hope of news for the ensuing 30 days after his buy. Better than living in the hope of news dropping any time.